Literature DB >> 2570603

The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates.

E Tanaka1, K Nakamura.   

Abstract

The effect of pretreatment for 7 days with either roxatidine acetate 75 mg twice daily or cimetidine 200 mg four times daily on the kinetics of antipyrine (AP), trimethadione (TMO) and indocyanine green (ICG) was studied in seven healthy, male, nonsmoking subjects. After pretreatment with cimetidine, the plasma clearances (CL) of AP and TMO were significantly lower and the elimination half-life (t1/2) of AP was significantly increased. The volumes of distribution (V) of AP and TMO were not affected. After roxatidine acetate, the pharmacokinetics of AP and TMO were unchanged. The cumulative renal excretion (% dose) and formation clearance of 3-hydroxymethyl-3-nor-antipyrine (NORA) were lowered by cimetidine treatment, but not following the administration of roxatidine acetate. ICG clearance was not changed significantly by either pretreatment. The results of this study show that roxatidine acetate does not impair the metabolism of three model substrates used to assess hepatic drug clearance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570603      PMCID: PMC1379900          DOI: 10.1111/j.1365-2125.1989.tb05411.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

Review 2.  Interaction of roxatidine acetate with antacids, food and other drugs.

Authors:  R A Labs
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Comparative effects of famotidine and cimetidine on trimethadione metabolism in the rat.

Authors:  E Tanaka; S Misawa; Y Kuroiwa
Journal:  Biochem Pharmacol       Date:  1986-03-01       Impact factor: 5.858

4.  Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine.

Authors:  M W Teunissen; J E Meerburg-van der Torren; N P Vermeulen; D D Breimer
Journal:  J Chromatogr       Date:  1983-12-09

Review 5.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

6.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.

Authors:  M W Teunissen; C H Kleinbloesem; L G de Leede; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Effects of cimetidine and ranitidine on trimethadione metabolism in the rat.

Authors:  E Tanaka; S Misawa
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1985-03

9.  Reduction of liver blood flow and propranolol metabolism by cimetidine.

Authors:  J Feely; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

10.  Trimethadione tolerance test for evaluation of functional reserve of the liver in patients with liver cirrhosis and esophageal varices.

Authors:  E Tanaka; A Ishikawa; A Ono; T Okamura; S Kobayashi; H Yasuhara; S Misawa
Journal:  J Pharmacobiodyn       Date:  1986-03
View more
  2 in total

Review 1.  Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.

Authors:  Robert B Cotton; Lisa P Shah; Stanley D Poole; Noah J Ehinger; Naoko Brown; Elaine L Shelton; James C Slaughter; H Scott Baldwin; Bibhash C Paria; Jeff Reese
Journal:  J Mol Cell Cardiol       Date:  2013-02-27       Impact factor: 5.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.